Company · CIK 0001737953 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Replimune Group, Inc. · REPL
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 GForm 4 → | Aug 24, 7:48 pm EDT | Philip Astley-SparkeDirector | 50,000 | — | — | 1,362,414 | — | |
| Aug 17, 2026 SForm 4 → | Aug 19, 6:42 pm EDT | Emily Luisa HillChief Financial Officer | 9,256 | $14.28 | $132,176 | 215,852 | −4.11% | |
| Aug 10, 2026 SForm 4 → | Aug 12, 5:07 pm EDT | Sushil PatelChief Executive Officer, Director | 39,341 | $12.97 | $510,253 | 708,151 | −5.26% | |
| Aug 10, 2026 SForm 4 → | Aug 12, 5:06 pm EDT | Emily Luisa HillChief Financial Officer | 11,448 | $12.97 | $148,481 | 225,108 | −4.84% | |
| Aug 10, 2026 SForm 4 → | Aug 12, 5:05 pm EDT | Konstantinos XynosChief Medical Officer | 11,447 | $12.97 | $148,468 | 224,215 | −4.86% | |
| Aug 10, 2026 SForm 4 → | Aug 12, 5:04 pm EDT | Andrew SchwendenmanChief Accounting Officer | 7,632 | $12.97 | $98,987 | 99,425 | −7.13% | |
| Jun 1, 2026 SForm 4 → | Jun 3, 8:30 pm EDT | Christopher SarchiChief Commercial Officer | 12,000 | $9.24 | $110,880 | 180,962 | −6.22% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 PForm 4 → | Aug 11, 5:46 pm EDT | BAKER BROS. ADVISORS LP +5Director, 10% Owner | 2,736,340 | $12.06 | $32,999,987 | 2,609,946 | — |